



3rd Annual

Gene Therapy for Ophthalmic Disorders

September 13-16, 2022

Boston, MA

Revolutionizing Genetic Therapy Development & Delivery to the Eye

Your 40+ Expert Speakers Include:



Daniel Chung
Chief Medical Officer
SparingVision



Shannon Boye
Founder & Director
Atsena Therapeutics



Steve Pakola
Chief Medical Officer
REGENXBIO



Theresa Heah
President & Chief Medical Officer,
Ophthalmology
Kriya Therapeutics



Richard Beckman
Chief Medical Officer
Adverum



Catherine O'Riordan
Head Translation Cluster, Genomics Unit
Sanofi



Stylianos Michalakis
Co-Founder & Chief Scientific Advisor
ViGeneron



Abraham Scaria
Chief Scientific Officer
AGTC



Hemant Khanna
Vice President of Preclinical Ocular Research
IVERIC Bio

REGISTER NOW!

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTRATION

Proud to Partner With:

FORGE
BIOLOGICS

NEWCELLS



EXPERIMENTICA
Scientific Excellence in Ocular Models™



TRANSLATIONAL
IMAGING
INNOVATIONS

ocugen

Biomere

cyagen
We help you discover life

Media Partner:

Macular Society
Beating Macular Disease

www.genetherapy-ophthalmology.com T +1 617 455 4188 E info@hansonwade.com @GeneTherapy



WELCOME TO THE 3RD ANNUAL GENE THERAPY FOR OPHTHALMIC DISORDERS

2nd Gene Therapy for Ophthalmic Disorders Attendees Said:

“Very informative and
interesting”

GenSight

“Outstanding meeting. The
science was great, but it was
also very well run”

Foundation Fighting Blindness

“High quality, relevant, and
up-to-date presentations
from leaders in ophthalmic
gene therapy provided an
informative and insightful
virtual meeting experience”

AbbVie

Discovering Next Generation Administration Routes for the Eye; Overcoming the Translational Challenges of Ophthalmic Preclinical Models; & Discussing Toxicity & Targeting Challenges of Vector-Based Approaches

The ophthalmology field is bursting with novel genetic approaches for targeting many disorders, with gene therapy taking centre stage as a one-time treatment option. With more invasive subretinal approaches being used in the clinic, as well as more innovative outpatient methods such as suprachoroidal delivery, there are a lot of pros and cons to discuss as the field progresses towards developing efficacious and durable treatments for many ophthalmic disorders.

Returning for its 3rd year, the **Gene Therapy for Ophthalmic Disorders** is the definitive forum for those working on ophthalmic gene therapy. This is the only conference that unites pharma and biotech to address the most pressing challenges, with focus on discussing and sharing solutions with the key leaders in the industry.

This year we have expanded into two streams of learning, putting more emphasis on the individual challenges faced in both the preclinical and clinical phases of ophthalmic gene therapy drug development.

Gene therapy for ophthalmic disorders has only seen one FDA approved therapy, which drug will be the next? **Join 110+ of your peers** to discuss and overcome the barriers preventing drugs getting to market.

Leave the definitive **3rd Annual Gene Therapy for Ophthalmic Disorders** forum equipped with knowledge of **novel methods and developments, actionable lessons** learned and **new connections**. Don't miss your opportunity to be a part the conversation which could lead to the **next drug approval**.

Your Top 5 Reasons to Attend this Year's Gene Therapy for Ophthalmic Disorders Summit:

1

Uncover novel methods of capsid engineering with **Atsena Therapeutics**, **ViGeneron** and **IVERIC Bio**, showing the next generation of vector development

Engage in three, expert-lead workshops that will explore non-viral delivery modalities, retinal biomarkers for ophthalmic gene therapy and novel gene therapies for the protection of retinal ganglion cells, with workshop leaders from **Novartis**, **Intergalactic Therapeutics**, **Nanoscope Therapeutics** & **AXONIS Therapeutics**

2

3

Hear from Daniel Chung at **SparingVision**, on how to develop an effective patient outreach program that ensures patient comprehension and input in clinical development

Explore the use of immunosuppressants and anti-inflammatory agents in aiding preclinical safety data with **Janssen**, **Northern Biomedical Research** & **Novartis**

4

5

Discover the next generation of technology and devices being used in the delivery of ophthalmic gene therapy from **Clearside Biomedical**, **REGENXBIO**, **University of Oxford** and **Everads Therapy** during our highly anticipated post-conference delivery day

YOUR EXPERT SPEAKERS

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTRATION



Abraham Scaria
Chief Scientific Officer
AGTC



Aniz Girach
Chief Medical Officer
ProQR



Arun Upadhyay
Chief Scientific Officer
Ocugen



Ashwath Jayagopal
Chief Scientific Officer
Opus Genetics



Catherine O'Riordan
Head Translational
Cluster, Genomics
Medicine Unit
Sanofi



Cathleen Gonzales
Director of
Pharmacology
**Intergalactic
Therapeutics**



Claire Gelfman
Chief Scientific Officer
**Foundation Fighting
Blindness**



Daniel Chung
Chief Medical Officer
SparingVision



Erin O'Neil
Vice President of Clinical
Development
Opus Genetics



Gayathri Ramaswamy
Vice President, Drug
Discovery & Disease
Biology
**Intergalactic
Therapeutics**



Gerard Caelles
Chief Business Officer
SpliceBio



Hemant Khanna
Vice President, Pre-
Clinica Ocular Research
IVERIC Bio



Jake Ternent
Patient
Luxturna Patient (UK)



Jasmina Kapetanovic
Clinician & Consultant
Vitreous-Retinal Surgeon
University of Oxford



Lauren Ayton
Associate Professor,
& Head - Vision
Optimisation
University of Melbourne



Lee Morris
Patient
Luxturna Patient (UK)



Shannon Boye
Founder & Director
Atsena Therapeutics



Maen Obeidat
Executive Director -
Therapeutics Area Head,
Biomarker Development,
Ophthalmology
Novartis (NIBR)



Magali Taiel
Chief Medical Officer
Gensight Biologics



Mark Peters
Chief Executive Officer
**Aevitas Therapeutics
(Formerly)**



Matthew Wood
Patient
Luxturna Patient (UK)



Rachel Eclov
Gene Therapy
Development Project
Leader
Kriya Therapeutics



Richard Beckman
Chief Medical Officer
Adverum



Samarendra Mohanty
Chief Scientific Officer &
President
Nanoscope Therapeutics



Sanghoon Kim
Project Engineer
**Nanoscope
Therapeutics**

YOUR EXPERT SPEAKERS



Stephen Poor
Director of External
Innovation and
Translational Biomarkers
Novartis (NIBR)



Steve Pakola
Chief Medical Officer
REGENXBIO



Stylianos Michalakis
Co-Founder & Chief
Scientific Advisor
ViGeneron



Subrata Batabyal
Senior Technical Officer
**Nanoscope
Therapeutics**



Theresa Heah
President & Chief
Medical Officer,
Ophthalmology
Kriya Therapeutics



Viral Kansara
Vice President of
Preclinical Development
Clearts Biomedical



William Beltran
Director, Division of
Experimental Retinal
Therapies
**University of
Pennsylvania**



Yoreh Barak
Director of Retina,
Department of
Ophthalmology
Everads Therapy



Nida Sen
Senior Director, Retina
Clinical Lead
Janssen



Jake Ternent
Patient
Luxturna Patient (UK)



Diane Doughty
Director of Device
Development
REGENXBIO



**Ramkumar
Ramamirtham**
Associate Director &
Optometrist
Novartis (NIBR)



Shane Hegarty
Chief Scientific Officer &
Co-Founder,
AXONIS Therapeutics



Catherine Cukras
Director, Medical Retinal
Fellowship Program
**National Eye Institute
(NEI)**



Catarina Santos
Medical Director of
Ophthalmology, Europe
Novartis



Amy Mawdesley
Product Manager
Newcells Biotech



Brianna Barrett
Associate Director of
Technical Sales
Forge Biologics



Eric Buckland
Founder & Chief
Executive Officer
**Translational Imaging
Innovations (TII)**



Simon Kaja
Chief Scientific Officer &
Vice President
Experimentica



Miquel Vila-Perello
Chief Executive Officer &
Chief Scientific Officer
SpliceBio

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTRATION

PRE-CONFERENCE WORKSHOP DAY TUESDAY, SEPTEMBER 13, 2022

These workshops will offer a one-day vital learning experience to establish the most critical areas of ophthalmic gene therapy research and development. Designed to help established and new companies understand a range of important topics in a greater depth than the main conference allows, giving you more time for discussion and to ask your burning questions.

These workshop will provide:

- Insight and discussion from companies working non-viral vector therapies
- Exploration into biomarkers utilized in ophthalmic gene therapy clinical trials
- Discovering the use of gene therapy to protect and repair retinal ganglion cells and a novel optic nerve crush model

WORKSHOP A

8:30 - 11:00

Discussing the Use of Non-Viral Gene Delivery as a Therapeutic Modality to the Eye

- Reviewing the conventional approaches of non-viral delivery (microinjection, electroporation, lipofection)-advantages and limitations
- Laser based approach for non-viral targeted delivery-safety and efficacy
- Clinical translation roadmap of image-guided laser-based gene delivery-safety, regulatory path

Subrata Batabyal, Senior Technical Officer, **Nanoscope Therapeutics**

Sanghoon Kim, Project Engineer, **Nanoscope Therapeutics**

Gayathri Ramaswamy, VP, Drug Discovery & Disease Biology, **Intergalactic Therapeutics**

WORKSHOP B

11:30 - 2:00

Preclinical Advances, Challenges & Tools for Developing Novel Gene Therapies for Retinal Ganglion Cell Neuroprotection, Regeneration and Repair In Optic Neuropathies

- State of the art on retinal ganglion cell neuroprotection and regeneration
- Challenges remaining for retinal ganglion cell repair in optic neuropathies
- AAV-CRISPR screening in optic nerve crush model for identification of novel gene therapy candidates

Shane Hegarty, Chief Scientific Officer & Co-Founder, **AXONIS Therapeutics**

WORKSHOP C

2:30-5:00

Opportunities & Challenges for Ocular, Systemic, Functional & Structural Biomarkers for Retina Indications

- What are the challenges in IRD trials?
- Functional and structural end points for IRD, past, present and future
- Physical demonstration of select low vision tests
- Biomarkers in clinical development

Stephen Poor, Director of External Innovation and Translational Biomarkers, **Novartis Institutes for BioMedical Research**

Maen Obeidat, Executive Director – Therapeutics Area Head, Biomarker Development, Ophthalmology, **Novartis Institutes for BioMedical Research**

Ramkumar Ramamirtham, Associate Director & Optometrist, **Novartis Institutes for BioMedical Research**

CONFERENCE DAY ONE - WEDNESDAY, SEPTEMBER 14, 2022

8.15 Chairs Opening Remarks



Daniel Chung
Chief Medical Officer
SparingVision

Overviewing Recent Developments In The Ophthalmic Gene Therapy Space

8.25 Panel Discussion: Gene Therapy for Ophthalmic Disorders – A Year in Review

- Developments and setback in the last 12 months
- Overview of instrumental work that has worked towards solving major issues
- Discussing the sustainability of ophthalmic gene therapy
- What does the coming year look like?

Moderator:

Daniel Chung
Chief Medical Officer
SparingVision



Theresa Heah
President &
Chief Medical
Officer,
Ophthalmology
**Kriya
Therapeutics**



Markus Peters
Chief Executive
Officer
**Aevitas
Therapeutics
(Formerly)**



**Samarendra
Mohanty**
Chief Scientific
Officer &
President
**Nanoscope
Therapeutics**



**Catherine
O'Riordan**
Head
Translational
Cluster, Genomics
Medicine Unit
Sanofi



Claire Gelfman
Chief Scientific
Officer
**Foundation
Fighting
Blindness**

9.15 Highlighting the Modifier Gene Therapy Approach for the Treatment of Retinitis Pigmentosa

- Discussing the preclinical data of our Retinitis Pigmentosa treatment
- Reviewing the early clinical data and outlining their indications
- Explaining the science behind the modifier gene therapy approach



Arun Upadhyay
Chief Scientific Officer
Ocugen

9.45 Evaluating Gene Therapy Assets in Preclinical Ocular Models

- Species considerations for drug development of ocular gene therapy assets
- Ocular routes of delivery for gene therapy in preclinical model
- Efficacy and safety assessment of gene therapy assets in preclinical ocular models



Simon Kaja
Chief Scientific Officer &
Vice-President
Experimentica

9.55 Utilizing Gene Therapy to Induce Long-Term Treatment of Wet AMD & Diabetic Retinopathy

- Outline the RGX-314 gene therapy program
- Discussing why suprachoroidal/subretinal delivery are optimal for this treatment
- Reviewing the current clinical data from Phase III clinical trials



Stephen Pakola
Chief Medical Officer
REGENXBIO

10.25 Speed Networking

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the gene therapy ophthalmic field and establish meaningful business relationships to pursue for the rest of the conference.

11.25 Coffee Break

PRECLINICAL STREAM

Chair: **Shannon Boye**, Founder & Director, **Atsena Therapeutics**

Examining Current & Next Generation Disease Models for the Eye to Provide Better Translational Data

11.55 Highlighting the Most Efficacious Animal Models for Testing the Inflammatory Response of Gene Therapy Delivery to the Eye

- Considerations for model development
- Testing of anti-inflammatory therapy in a mouse model
- Observed challenges and next steps

Rachel Eclov, Gene Therapy Development Project Leader, **Kriya Therapeutics**

12.25 Discovering Canine Models for Inherited Retinal Diseases to Evaluate Retinal Gene Therapies

- Natural history of disease in dogs versus humans
- Route of delivery of AAV-mediated gene therapy
- Outcome measures of efficacy/safety studies in dogs

William Beltran, Director, Division of Experimental Retinal Therapies, **University of Pennsylvania**

CLINICAL STREAM

Chair: **Daniel Chung**, Chief Medical Officer, **SparingVision**

Mastering Patient Outreach & Enrolment for Better Communication with the Drug Recipients

11.55 Creating an Effective Patient Outreach Programme to Ensure Patient Comprehension & Input into Clinical Development

- Exploring appropriate methods of patient outreach
- Building relationships with Patient Advocacy groups
- Discovering the best methodology of ensuring patient education and expectations
- Benchmarking and recognizing the importance of the patient's voice in clinical development

Daniel Chung, Chief Medical Officer, **SparingVision**

12.25 Looking Into Patient Perspectives on Ocular Gene Therapy

- Development and validation of the Attitudes to Gene Therapy – Eye (AGT-EYE) tool
- Results of an Australian national survey of almost 700 people with IRDs and/or their carers on the knowledge and perspectives on gene therapy
- How can academics and industry work more closely with people with IRDs to codesign research and clinical trials?

Lauren Ayton, Associate Professor, & Head – Vision Optimisation, **University of Melbourne**

CONFERENCE DAY ONE - WEDNESDAY, SEPTEMBER 14, 2022

12.55 Lunch Break & Networking

Exploring Novel Developments in Vector Engineering & Selection to Benchmark New Therapeutic Platforms

1.55 Sharing Approaches for Splice Regulation & Modular Protein Function in Retinal Gene Therapy

- Limitations of AAV payload capacity
- Concept of miniaturizing large genes for AAV packageability
- Modular protein function as a modality to design minigenes

Hemant Khanna, Vice President, Preclinical Ocular Research, **IVERIC Bio**

Approaching Commercial Challenges of Ophthalmic Gene Therapies to Help your Product Reach Market

1.55 Attracting Financial Investment for Biotech Startups: the Case of SpliceBio

- Walking through a case study of an exciting and promising new genetic platform in ophthalmology
- Sharing the processes involved in attaining investment for a novel idea in a competitive field
- Showcasing innovating science to overcome the payload capacity of the AAV vectors to demonstrate a competitive edge in ophthalmology

Gerard Caelles, Chief Business Officer, **SpliceBio**

2.25 Addressing the Unmet Need in Retinal Gene Therapy: Focus on IVT Delivery & Cargo capacity of AAV Vectors

- Overview of the benefits and limitations of AAV vectors and unmet needs in retinal gene therapy
- Introduction and update on next generation vgAAV-AAV capsids
- Introduction to REVERT dual AAV technology

Stylianios Michalakakis, Co-founder & Chief Scientific Advisor, **ViGeneron**

2.25 Understanding Gene Therapy After the Data: How Does it Reach the People in Need?

- Main issues in the implementation of innovative gene therapies from the country perspective (Payers, Doctors and Patients)
- Main opportunities of improvement - what have we learned so far?

Catarina Santos, Medical Director of Ophthalmology, **Europe, Novartis**

Remote

2.55 Tropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids

- The advantages of iPSC-derived human retinal organoids as an in vitro preclinical model
- The utility of iPSC-derived retinal organoids in gene therapy applications
- Expansion of AAV capsid and transgene options for preclinical testing of gene therapy

Amy Mawdesley Product Manager, **Newcells Biotech**

2.55 Establishing a Sustainable Gene Therapy Pipeline for Inherited Retinal Diseases

- Challenges and solutions for creating a sustainable gene therapy pipeline for rare inherited retinal diseases
- Opus Genetics' gene therapy portfolio for LCA and other classes of IRDs
- Outlining phase I clinical trial data for LCA5-IRD

Ash Jayagopal, Chief Scientific Officer, **Opus Genetics**

3.05 Exploring the Laterally Spreading AAV.SPR Capsid for Treatment of Inherited Retinal Diseases

- Outlining the efficacy features of this novel capsid
- Detailing the safety features of AAV.SPR capsid

Shannon Boye, Founder & Director, **Atsena Therapeutics**

3.35 Afternoon Refreshments

4.05 Panel Discussion: Ophthalmic Gene Therapy Patient Perspective

- Do patients feel they know what treatments are available to them?
- Is there trial data available to patients so they can decide if they want to participate?
- How can an open line of communication be developed between patients and the industry?



Jake Ternent

Patient

Luxturna Patient (UK)



Matthew Wood

Patient

Luxturna Patient (UK)



Lee Morris

Patient

Luxturna Patient (UK)

Moderator:



Jasmina Kepatanovic

Clinician, Scientist & Consultant Vitreo-Retinal Surgeon

University of Oxford

CONFERENCE DAY ONE - WEDNESDAY, SEPTEMBER 14, 2022

WELCOME

4.35

Efficient Gene Therapy Manufacturing for Ocular Diseases

- Targeting sensitive biological spaces, such as the eye, require highly purified and well characterized products
- AAV therapeutics for ophthalmic dosing require low endotoxin, residuals, and empty particle contaminant levels
- Scalable processes that maintain high productivity and purity of the vector



Brianna Barrett
Associate Director of
Technical Sales
Forge Biologics

4.45

Exploring the Use of Gene Therapy to Treat Dry AMD

- Comparing treatment for Wet AMD vs. Dry AMD
- Outlining the role of complement system in Dry AMD
- Displaying gene delivery of complement factor H



Abraham Scaria
Chief Scientific Officer
AGTC

5.15

End of Conference Day One: Chair's Closing Remarks



Daniel Chung
Chief Medical Officer
SpringVision

5:30

Scientific Poster Session & Drinks Reception

After the formal presentations have finished for the afternoon, the learning and networking carries on. The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on the latest advancements in the gene therapy for ophthalmic disorders field.



SPEAKERS

AGENDA

PARTNER WITH US

REGISTRATION

“The update by outstanding speakers demonstrated the tremendous momentum in the field of ophthalmic gene therapy”

Horama

CONFERENCE DAY TWO - THURSDAY, SEPTEMBER 15, 2022

WELCOME

8.50 Chairs Opening Remarks



Claire Gelfman
Chief Scientific Officer
Foundation Fighting Blindness

Utilizing Gene Therapy to Restore Protein Function in Common Ophthalmic Disorders to Generate Therapies with a Large Patient Population

9.00 Exploring Ambient Light Activatable Optogenetics for Vision Restoration in Retinal Degenerative Diseases

- Mutation-agnostic therapy with potential to be disease-agnostic platform therapy preclinical data
- Clinical data on Retinitis Pigmentosa
- Novel end points for low vision patients deployed in a multi-site randomized, sham-controlled optogenetic study



Samarendra Mohanty
Chief Scientific Officer & President
Nanoscope Therapeutics

9.30 Showcasing ADVIM-022 as a Treatment for Neovascular AMD

- Wet AMD: the rationale for using gene therapy for treatment
- Utilizing aAV.7m8 vector for intravitreal administration and preclinical and clinical support for dosing
- Clinical experience with ADVIM-022 in Wet AMD



Richard Beckman
Chief Medical Officer
Adverum

10.00 Providing an Update on Antisense Oligonucleotides for Inherited Retinal Disease

- Antisense oligonucleotides have so much promise in Ph1/2 clinical trials in LCA10 and Usher's Syndrome
- Recent interim analyses in key trials have shed much light on mechanism of action of antisense oligonucleotides
- Overview of the data available from clinical trials
- Clinical trial endpoints for inherited retinal diseases



Aniz Girach
Chief Medical Officer
ProQR

10.30 Morning Break & Networking

PRECLINICAL STREAM

Chair: **Gayathri Ramaswamy**, Vice President, Drug Discovery & Disease Biology, **Intergalactic Therapeutics**

Controlling Inflammation & Toxicity to Provide a Safer Treatments for the Eye

11.30 Building In Vivo Pharmacology For Targeting ABCA4 to the Retina Using a Novel Non-viral DNA/Delivery Approach

- Discuss Intergalactic's non-viral gene therapy platform for ocular indications
- Discuss strategy for retina in vivo pharmacology studies using large animal species
- Demonstrate delivery of the target gene to the relevant cell type in the retina
- Assess the impact of the delivery method on retinal structure

Cathleen Gonzales, Director of Pharmacology, **Intergalactic Therapeutics**

12.00 Round-Table Discussion: Discussing the Immunogenicity of the Eye

- Discussing the implications of treatments delivery to the immuno-privileged eye
- What are the most common causes of inflammation?
- How do we overcome ocular inflammation - is it possible?

Richard Beckman, Chief Medical Officer, **Adverum**

CLINICAL STREAM

Chair: **Claire Gelfman**, Chief Scientific Officer, **Foundation Fighting Blindness**

Benchmarking Ophthalmic Clinical Trial Design to Get your Therapy to Market

11.30 Identifying the Right Endpoints for your Therapy to Optimize your Clinical Trials

- Proposing a framework to select disease-specific and stage-specific endpoints including comparison measures
- Reviewing strengths and limitations of visual function tests currently used as outcome measures
- Addressing practical aspects of measuring outcomes to minimize patient burden

Erin O'Neil, Vice President of Clinical Development, **Opus Genetics**

12.00 Data Solutions for Imaging Biomarker Discovery and Clinical Endpoint Validation

- Dearth of meaningful endpoints remains hurdle in ophthalmic gene therapy trials
- Biomarkers and endpoints are not born, they are discovered and validated
- Clinical standards of care are insufficient, and must be supported with emerging imaging modalities and analyses

Eric Buckland, Founder & Chief Executive Officer, **Translational Imaging Innovations (TII)**

SPEAKERS

AGENDA

PARTNER WITH US

REGISTRATION

CONFERENCE DAY TWO - THURSDAY, SEPTEMBER 15, 2022



12.10 Clinical Trial Development for Interventional Study in Outer Retinal Degenerative Diseases

- Overview of the unmet need in clinical trial outcomes
- Dark adaptation as a potential outcome for intermediate AMD
- Structural and Functional parameters in X-linked retinoschisis

Catherine Cukras, Director, Medical Retina Fellowship Program, National Eye Institute (NEI)

1.00 Lunch Break & Networking

Discussing the Successes & Learning Opportunities of Recent Therapies to Further Understanding of the Correct Protocols of Ophthalmic Gene Therapy Translation

2.00 Discussing the Involvement of Immunosuppressants in Therapies to Understand the Benefits & Drawbacks

- Anti-inflammatory and immunosuppressives as prophylaxis for gene therapy associated inflammation
- Management of treatment emergent gene therapy associated inflammation
- Translational aspects of inflammation to guide immunosuppressive therapy decisions



Nida Sen
Senior Director, Retina Clinical Lead
Janssen

2.30 Delving Into Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy

- LHON, a rare disease with unmet medical need
- Final steps of Lumevoq clinical development
- Importance of early access programs



Magali Taiel
Chief Medical Officer
GenSight Biologics

Remote

3.00 Understand the Novel Protein Splicing Platform that Overcomes the Payload Capacity of AAV-Vectors

- Outlining the methodology of protein splicing
- Discovering split inteins: auto processing domains
- Exploring protein splicing as a novel gene therapy modality to the eye



Miquel Vila-Perello
Chief Executive Officer & Chief Scientific Officer
SpliceBio

3.30 End of Conference Day Two: Chair's Closing Remarks



Claire Gelfman
Chief Scientific Officer
Foundation Fighting Blindness

"It was a very informative and intellectual discussion on the future of medicine"

Regeneron

POST-CONFERENCE DELIVERY DAY

FRIDAY, SEPTEMBER 16

This day will offer a one-day technology and device centred insight experience to establish the most critical areas of ophthalmic gene therapy research and development. Designed to help established and new companies understand a range of important topics.

This day will provide:

- Insight into the technology used to develop the methods of delivery
- An deeper understanding of subretinal administration for gene therapies to the eye
- Surgical perspective on the key criteria for suprachoroidal delivery
- Exploration of surgical and robot assisted delivery of gene therapy

9.50

Chairs Opening Remarks



Viral Kansara
Vice President of Preclinical Development
Clearside Biomedical

Exploring the Technologies & Devices Involved with Suprachoroidal Delivery to Prepare for the Next Generational Delivery Route

10.00

Recent Updates on Microinjector Based Suprachoroidal Gene Therapy: Potentials & Challenges

- SCS microinjector based suprachoroidal gene delivery enables minimally invasive office-based treatment for choroiretinal diseases
- Nanoparticle based non-viral gene delivery via SC injection has potential to be a repeatable office-based gene therapy



Viral Kansara
Vice President of Preclinical Development
Clearside Biomedical

10.30

Novel Suprachoroidal Delivery System Enables Rapid Distribution to the Posterior Segment & Macula

- Considerations for rapid and broad distribution to posterior segment when delivering gene therapy
- Innovative approach for suprachoroidal delivery using Everads' suprachoroidal delivery system
- Perspectives of a retinal surgeon on key criteria for a suprachoroidal delivery technology



Yoreh Barak
Director of Retina, Department of Ophthalmology
Everads Therapy

11.00

Morning Break

Exploring Novel Technology & Devices Involved with Ophthalmic AAV-Mediated Delivery

11.30

Looking Into Surgical & Robot-assisted Delivery of Gene Therapy Vectors

- Clinical methods of AAV-mediated delivery
- Gene therapy and optogenetic approaches
- Robot-assisted delivery method



Jasmina Kapetanovic
Clinician, Scientist & Consultant Vitreo-Retinal Surgeon
University of Oxford

12.00

Exploring the Use of Subretinal Administration for Ophthalmic Gene Therapy

- Summarizing the use of subretinal and suprachoroidal administration for gene therapy
- Reviewing the current and emerging technologies for subretinal administration
- Device development considerations for subretinal delivery



Diane Doughty
Director of Device Development
REGENXBIO

12.30

Lunch Break & Networking

Grab your lunch, join a table and introduce yourself to share your views with your fellow gene therapy experts

1.30

Panel Discussion: Discussing the Future of AAV-Mediated Delivery

- Addressing the future of delivery – suprachoroidal, subretinal and robot assisted methods
- Discussing the suitability of subretinal delivery
- How can we make delivery more effective in the future?



Jasmina Kapetanovic
Clinician, Scientist & Consultant Vitreo-Retinal Surgeon
University of Oxford



Viral Kansara
Vice President of Preclinical Development
Clearside Biomedical



Yoreh Barak
Director of Retina, Department of Ophthalmology
Everads Therapy

2.00

End of Post-Conference Delivery Day



Viral Kansara
Vice President of Preclinical Development
Clearside Biomedical

WHY PARTNER

Elevate Your Brand & Have Your Services Showcased in Front of the Leading Experts in the Field of Ophthalmic Gene Therapy


Partnering with the **3rd Annual Gene Therapy for Ophthalmic Disorders** conference is a prime opportunity to demonstrate the availability and reliability the industry is looking for in service providers.

Elevate your brand and show how you can enable drug developers to overcome the barriers preventing their drugs reaching the patients with

ophthalmic disorders. This could involve speaking on the agenda, hosting networking sessions or creating exhibitions. **We'll work with you to develop a bespoke partnership** to ensure you meet your business objectives.

Get in touch today to learn more about how we can help you to create the most valuable connections within the ophthalmic gene therapy industry.


WHO WILL YOU MEET?



AUDIENCE SENIORITY*

- C-Level – 15%
- VP – 11%
- Senior Director/Director – 24%
- Scientist – 17%

Based on 2021 Gene Therapy for Ophthalmic Disorders attendees



ATTENDING COMPANIES*

- Drug Developer 38%
- Healthcare Providers – 27%
- Service Providers – 7%
- Other – 28%

LAST YEAR'S ATTENDING COMPANIES



GET INVOLVED

Adam Haras-Gummer
Senior Partnership Director
sponsor@hansonwade.com / (+1) 617 455 4188



2022 PARTNERS



FORGE BIOLOGICS INNOVATION PARTNER

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge's mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 ft² facility in Columbus, Ohio, "The Hearth," to serve as its headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

www.forgebiologics.com



NEWCELLS BIOTECH INNOVATION PARTNER

Newcells Biotech are a fast-growing team of global scientific and industry experts based in the Helix Science Campus of Newcastle-upon-Tyne in the UK. We provide in vitro models to most accurately predict in vivo outcomes, building confidence in the decision making process. Using our expertise in iPSCs, cellular physiology and organoid technology, we have built functional pre-clinical in vitro models of the retina in the form of fully developed retinal organoids and RPE cells.

www.newcellsbiotech.co.uk



EXPERIMENTICA INNOVATION PARTNER

Experimentica is a global CRO developing and offering novel preclinical ocular models and services to sponsors from Pharma, Biotech, and Academia. We offer an industry-leading portfolio of in vivo, in vitro, and ex vivo PoC models in rodents and larger animals, as well as custom models, PK/PD, and Toxicity ocular studies. Our laboratory sites are located in Finland, Lithuania, and the United States. This enables our team of interdisciplinary scientists to understand and support local and international companies fully.

www.experimentica.com



TRANSLATIONAL IMAGING INNOVATIONS (TII) INNOVATION PARTNER

Translational Imaging Innovations, Inc. (TII) was formed in 2019 as a spin-out of the Advanced Ocular Imaging Program of the Medical College of Wisconsin to accelerate image-driven innovations in ophthalmology. The TII Integrated Translational Imaging™ platform combines a scalable and extensible database with data automation workflows for biomarker discovery and clinical endpoint validation. Our objective is to dramatically increase access to ophthalmic images and data for empowering breakthroughs in next-generation ocular therapies.

www.tiinnovations.com

2022 PARTNERS



OCUGEN
INDUSTRY PARTNER

At Ocugen, we are developing novel solutions to medical challenges, approaching healthcare innovation with purpose and agility to deliver new breakthroughs for people living with disease.

www.ocugen.com



BIOMERE
EVENT PARTNER

Our U.S. bi-coastal locations offer an extensive portfolio of preclinical research services from in vitro analyses, early discovery and proof-of-concept to discovery toxicology. Nonclinical capabilities include: pharmacokinetics, lead compound screening, proof of concept, efficacy assessment, pharmacology, mechanism of action, and early lead optimization. Biomere also provides supportive colony maintenance, backup colony support and on site room use agreements.

www.biomere.com



CYAGEN
EXHIBITION PARTNER

Founded in 2006, Cyagen is an innovative CRO enterprise that accelerates the research and development of new drugs with data, algorithms and animal models. Based on animal models and combined with the in-depth exploration of artificial intelligence, Cyagen is at the forefront of the industry in the field of gene editing animal models. Our comprehensive services cover the entire process of model generation: from transgenic/gene targeting strategy design, through model development, breeding, cryopreservation, and phenotype analysis. At the same time, Cyagen has continuously strengthened its advantages in data and models, and proactively deployed in the field of cell and gene therapy. Combining many high-tech platforms, such as target prediction and validation, viral vector development, evaluation model construction and effectiveness evaluation, we have also made significant achievements in this brand new field.

www.cyagen.com

“Very well-organized conference covering gene therapy vectors,
preclinical and clinical research and patient experience”

IVERIC Bio

READY TO REGISTER?

Please select appropriate price when booking. Bookings are subject to approval.

REGISTER BEFORE
MIDNIGHT,
SEPTEMBER 12 &
SAVE \$100!

Drug Developer Pricing*	STANDARD RATE	On The Door Rate
Full Access Pass (Conference + Workshop Day AND Post Event Delivery Day)	\$4,495 (save \$100)	\$4,595
Conference + Workshop Day OR Post Event Delivery Day	\$3,697 (save \$100)	\$3,797
Conference Only	\$2,899 (save \$100)	\$2,999

Please note: If you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.

All prices shown in USD.

Reduced rates are available for full-time academics. Please get in touch at info@hansonwade.com for more information or to apply.

*To be eligible for the drug developer price, the group or individual must be from a biotech or pharma company that has a publicly available pipeline, and does not offer pay for services

Multi-Pass Discounts

10% discount 3 passes	15% discount 4 passes	20% discount 5+ passes
--------------------------	--------------------------	---------------------------

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate. Contact: register@hansonwade.com

3 Easy Ways To Book

 genetherapy-ophthalmology.com  register@hansonwade.com  (+1) 617 455 4188

DoubleTree North Shore

50 Ferncroft Rd, Danvers, MA 01923, United States

For further information or assistance, please visit:

www.hilton.com/en/hotels/bosnsdt-doubletree-boston-north-shore/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH